DOLUTEGRAVIR; TENOFOVIR DISOPROXIL FUMARATE; LAMIVUDINE
Pre-Launchdolutegravir; tenofovir disoproxil fumarate; lamivudine
NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing three antiretroviral agents: dolutegravir (an integrase strand transfer inhibitor), tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor), and lamivudine (a nucleoside reverse transcriptase inhibitor). The combination is indicated for the treatment of HIV-1 infection in adults and adolescents. This regimen works by blocking viral replication through complementary mechanisms across three drug classes.
PRE_LAUNCH
Pre-launch stage presents opportunities for commercial planning, market access, and field preparation roles; team size and investment will depend on regulatory approval timeline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this product at pre-launch stage offers exposure to full commercialization strategy development, regulatory approval navigation, and market entry planning for an important therapeutic area. Career growth depends on successful product launch and ability to compete in the crowded HIV treatment market.
Brand ManagerMedical Science Liaison (MSL)
Worked on DOLUTEGRAVIR; TENOFOVIR DISOPROXIL FUMARATE; LAMIVUDINE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.